Genetically modified non-human animals and methods of use thereof
Genetically modified non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRPα and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
1. A genetically modified mouse, comprising:
a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human SIRPα protein and is operably linked to a SIRPα gene promoter; and
a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human IL-15 protein and is operably linked to an IL-15 gene promoter, wherein the genetically modified mouse expresses the human SIRPα protein and the human IL-15 protein.
2. The genetically modified mouse according to claim 1 , wherein the SIRPα gene promoter is an endogenous mouse SIRPα gene promoter at the mouse SIRPα gene locus.
3. The genetically modified mouse according to claim 1 , wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence that encodes the human SIRPα protein.
4. The genetically modified mouse according to claim 1 , wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence that encodes the human SIRPα protein.
5. The genetically modified mouse according to claim 1 , wherein the IL-15 gene promoter is an endogenous mouse IL-15 gene promoter at the mouse IL-15 gene locus.
6. The genetically modified mouse according to claim 5 , wherein the genetically modified mouse is heterozygous for the allele comprising the nucleic acid sequence that encodes the human IL-15 protein.
7. The genetically modified mouse according to claim 5 , wherein the genetically modified mouse is homozygous for the allele comprising the nucleic acid sequence that encodes the human IL-15 protein.
8. The genetically modified mouse according to claim 1 , wherein the nucleic acid sequence that encodes the human IL-15 protein comprises human IL-15 genomic coding and non-coding sequence.
9. The genetically modified mouse according to claim 1 , wherein the human IL-15 protein is a functional fragment of a full length human IL-15 protein.
10. The genetically modified mouse according to claim 1 , wherein the genetically modified mouse is immunodeficient.
11. The genetically modified mouse according to claim 10 , wherein the genetically modified mouse comprises a Rag2 gene knock-out.
12. The genetically modified mouse according to claim 10 , wherein the genetically modified mouse comprises an IL2rg gene knock-out.
13. The genetically modified mouse according to claim 1 , wherein the genetically modified mouse comprises an engraftment of human hematopoietic cells.
14. The genetically modified mouse according to claim 13 , wherein the genetically modified mouse comprises an infection with a human pathogen.
15. The genetically modified mouse according to claim 14 , wherein the human pathogen activates, induces and/or targets T cells and/or natural killer (NK) cells.
16. The genetically modified-mouse according to claim 14 , wherein the human pathogen is a pathogen that infects human intestine.
17. The genetically modified mouse according to claim 14 , wherein the pathogen infects human lung.
18. A method of making a mouse expressing a human IL-15 protein and a human SIRPα protein, comprising:
introducing into a genome of a first mouse a nucleic acid sequence encoding a human SIRPα protein, wherein the sequence encoding the human SIRPα protein is operably linked to an SIRPα gene promoter sequence;
introducing into a genome of a second mouse a nucleic acid sequence encoding a human IL-15 protein, wherein the sequence encoding the human IL-15 protein is operably linked to a IL-15 promoter sequence; and
breeding the first mouse and the second mouse to produce a third mouse that comprises the nucleic acid sequence encoding the human IL-15 protein and the nucleic acid sequence encoding the human SIRPα protein, wherein the third mouse expresses the human IL-15 protein and the human SIRPα protein.
19. The method of claim 18 , wherein the steps of introducing comprise generating a mouse from a pluripotent stem cell comprising the nucleic acid encoding human IL-15 or human SIRPα.
20. An animal engraftment model, comprising a genetically modified mouse comprising:
a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human SIRPα protein and is operably linked to a SIRPα gene promoter;
a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human IL-15 protein and is operably linked to an IL-15 gene promoter; and
an engraftment of human hematopoietic cells, wherein the genetically modified mouse (i) expresses the human SIRPα protein and the human IL-15 protein, and (ii) comprises human intraepithelial lymphocytes (IELs) in the small intestine and Peyer's patches of the genetically modified mouse.
21. A method of identifying an agent that inhibits an infection by a pathogen that activates, induces and/or targets human T cells and/or natural killer (NK) cells, the method comprising:
administering an agent to an genetically modified mouse, wherein the genetically modified mouse is deficient for an endogenous immune system and comprises:
(i) a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human SIRPα protein and is operably linked to a SIRPα gene promoter,
(ii) a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human IL-15 protein and is operably linked to an IL-15 gene promoter,
(iii) an engraftment of human hematopoietic cells, and
(iv) an infection by a pathogen that activates, induces and/or targets human T cells and/or natural killer cells, wherein the genetically modified mouse expresses the human SIRPα protein and the human IL-15 protein; and
determining whether the agent reduces the amount of the pathogen in the pathogen-infected mouse.
22. A method of determining the efficacy a candidate therapeutic antibody or antigen-binding protein in NK-cell mediated killing of a target cell, comprising:
administering the candidate therapeutic antibody or antigen-binding protein to a genetically modified mouse, wherein the genetically modified mouse is deficient for an endogenous immune system and comprises:
(i) a nucleic acid sequence incorporated into the genome of the genetically modified-mouse, which sequence encodes a human SIRPα protein and is operably linked to a SIRPα gene promoter,
(ii) a nucleic acid sequence incorporated into the genome of the genetically modified mouse, which sequence encodes a human IL-15 protein and is operably linked to an IL-15 gene promoter, and
(iii) an engraftment of human hematopoietic cells, wherein the genetically modified mouse expresses the human SIRPα protein and the human IL-15 protein; and
determining whether the candidate therapeutic antibody or antigen-binding protein activates NK cell antibody-dependent cellular cytotoxicity against the target cell in the genetically modified mouse.
23. The genetically modified mouse according to claim 2 , comprising a null mutation in the mouse SIRPα gene at the mouse SIRPα gene locus.
24. The genetically modified mouse according to claim 23 , wherein the null mutation is a deletion of at least mouse SIRPα exons 2-4.
25. The genetically modified mouse according to claim 1 , wherein the human SIRPα protein is a functional fragment of a full length human SIRPα protein.
26. The genetically modified mouse according to claim 25 , wherein the functional fragment comprises an extracellular domain of human SIRPα.
27. The genetically modified non-human animal according to claim 5 , comprising a null mutation in the non-human IL-15 gene at the non-human animal IL-15 gene locus.
28. The genetically modified mouse according to claim 27 , wherein the null mutation is a deletion of at least mouse IL-15 exons 5-8.